Published in Ther Adv Chronic Dis on September 01, 2012
The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm (2014) 1.76
A New Application of Parallel Synthesis Strategy for Discovery of Amide-Linked Small Molecules as Potent Chondroprotective Agents in TNF-α-Stimulated Chondrocytes. PLoS One (2016) 1.38
Biologic basis of osteoarthritis: state of the evidence. Curr Opin Rheumatol (2015) 0.98
Chitosan oligosaccharides inhibit IL-1β-induced chondrocyte apoptosis via the P38 MAPK signaling pathway. Glycoconj J (2016) 0.76
Diverse expression of selected cytokines and proteinases in synovial fluid obtained from osteoarthritic and healthy human knee joints. Eur J Med Res (2014) 0.76
Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord (2014) 0.76
Vitamin C Protects Chondrocytes against Monosodium Iodoacetate-Induced Osteoarthritis by Multiple Pathways. Int J Mol Sci (2016) 0.75
PROSPECTIVE EFFECT OF RED ALGAE, ACTINOTRICHIA FRAGILIS, AGAINST SOME OSTEOARTHRITIS AETIOLOGY. Afr J Tradit Complement Altern Med (2016) 0.75
Intra-articular Delivery of Antago-miR-483-5p Inhibits Osteoarthritis by Modulating Matrilin 3 and Tissue Inhibitor of Metalloproteinase 2. Mol Ther (2017) 0.75
The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell (2002) 6.81
Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol (2002) 5.73
Osteoarthritis. J Cell Physiol (2007) 5.55
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
The lipocalin protein family: structure and function. Biochem J (1996) 5.24
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol (2010) 5.14
Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem (1993) 4.90
Matrix metalloproteinases: role in arthritis. Front Biosci (2006) 4.52
The role of cytokines in osteoarthritis pathophysiology. Biorheology (2002) 4.28
The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem (2001) 3.48
Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res (2001) 3.09
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis (2008) 2.85
Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest (1995) 2.67
The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res (2001) 2.44
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res (2005) 2.14
Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood (1994) 2.14
Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta (2000) 2.06
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2009) 2.03
Collagenases in cancer. Biochimie (2005) 1.86
Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur Cell Mater (2011) 1.84
Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry (2000) 1.80
Matrix metalloproteinases and tumor progression. Adv Exp Med Biol (2003) 1.61
Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage (2011) 1.58
The pathophysiology of osteoarthritis. Aging Clin Exp Res (2003) 1.55
Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther (2006) 1.51
Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs (2003) 1.51
The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci (1998) 1.37
Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem (2010) 1.34
Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci (2011) 1.34
Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer (2007) 1.33
Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum (2007) 1.30
MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis (2005) 1.27
Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage (2005) 1.27
Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals (2006) 1.24
Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci (2002) 1.23
Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol (2011) 1.21
An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol (2011) 1.21
Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine (2007) 1.20
The siderocalin/enterobactin interaction: a link between mammalian immunity and bacterial iron transport. J Am Chem Soc (2008) 1.19
Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem (2006) 1.17
New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol (2010) 1.15
Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle (2009) 1.15
Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging (2010) 1.14
The effect of IL-1beta on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human chondrocytes. Life Sci (2005) 1.14
Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine (2011) 1.13
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther (2011) 1.12
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. Inflamm Res (2009) 1.12
Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer (2009) 1.11
New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem (2011) 1.10
Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets (2009) 1.08
A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage (2005) 1.07
Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord (2011) 1.05
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int (2010) 1.05
Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets (2007) 1.05
Matrix metalloproteinases: role in skeletal development and growth plate disorders. Front Biosci (2006) 1.03
Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res (2007) 1.03
Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets (2010) 1.02
Mammalian siderophores, siderophore-binding lipocalins, and the labile iron pool. J Biol Chem (2012) 1.00
The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol (1999) 0.99
Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee. Drugs Aging (2010) 0.99
Protein kinases in chondrocyte signaling and osteoarthritis. Clin Orthop Relat Res (2004) 0.99
Autolytic activation of recombinant human 72 kilodalton type IV collagenase. Biochemistry (1995) 0.98
Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis (2010) 0.98
Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem (1993) 0.97
Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs (2011) 0.96
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J Med Chem (2012) 0.96
Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med (2009) 0.93
Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn (1999) 0.93
Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins. Connect Tissue Res (2010) 0.93
Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. BMC Clin Pharmacol (2010) 0.92
Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci (2010) 0.91
Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes. Histol Histopathol (2004) 0.90
Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma. Exp Mol Pathol (2011) 0.88
Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem (2006) 0.88
Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol Histopathol (2011) 0.87
Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone (2004) 0.87
Dysfunctional Immune-Mediated Inflammation in Rheumatoid Arthritis Dictates that Development of Anti-Rheumatic Disease Drugs Target Multiple Intracellular Signaling Pathways. Antiinflamm Antiallergy Agents Med Chem (2011) 0.86
Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum (2009) 0.85
Changes in subchondral bone early in the development of osteoarthritis. Arthritis Rheum (2011) 0.83
Neutrophil gelatinase-associated lipocalin in gastric carcinoma cells and its induction by TPA are controlled by C/EBPβ. Biochem Cell Biol (2011) 0.81
NGAL is a precocious marker of therapeutic response. Curr Pharm Des (2011) 0.81
Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Curr Drug Metab (2011) 0.80
The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflamm (2010) 0.79
Gene expression and tibial dyschondroplasia. Poult Sci (2000) 0.79
Identification of new autolytic sites of recombinant truncated mature human fibroblast stromelysin by mass spectrometry. J Pept Res (1997) 0.76
Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med (2005) 1.55
Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum (2007) 1.30
Body mass index and blood glucose: correlations with serum insulin, growth hormone, and insulin-like growth factor-1 levels in patients with diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int (2005) 1.19
Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res (2003) 1.08
Hydrostatic pressure induces apoptosis in human chondrocytes from osteoarthritic cartilage through up-regulation of tumor necrosis factor-alpha, inducible nitric oxide synthase, p53, c-myc, and bax-alpha, and suppression of bcl-2. J Cell Biochem (2002) 1.06
Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum (2005) 0.89
Hydrostatic pressure increases apoptosis in cartilage-constructs produced from human osteoarthritic chondrocytes. Front Biosci (2006) 0.85
Intra-erythrocyte deposition of growth hormone in rheumatic diseases. Rheumatol Int (2002) 0.82
The serum growth hormone to somatostatin ratio is skewed upward in rheumatoid arthritis patients. Front Biosci (2004) 0.81
Growth hormone and insulin-like growth factor-I in symptomatic and asymptomatic patients with diffuse idiopathic skeletal hyperostosis (DISH). Front Biosci (2002) 0.80
Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int (2004) 0.78
Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med (2009) 0.78
Targeted drug development for arthritis. Future Med Chem (2012) 0.78
Age-related changes in serum growth hormone, insulin-like growth factor-1 and somatostatin in system lupus erythematosus. BMC Musculoskelet Disord (2004) 0.77
Comparison of proteoglycan and collagen in articular cartilage of horses with naturally developing osteochondrosis and healing osteochondral fragments of experimentally induced fractures. Am J Vet Res (2005) 0.77
The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr Rheumatol Rev (2013) 0.76